MT Newswires50d agoneutral
AbbVie Trims Full-Year Profit Outlook Due to Apogee AcquisitionAbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
66last 24h
973last 7d
109● bullish (7d)
123● bearish (7d)
212publishers
BioPharma Dive50d agoneutral
Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOsSanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
BioPharma Dive68d agobullish
Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
BioPharma Dive88d agoneutral
How Kardigan spun deal leftovers into a $400M IPOCEO Tassos Gianakakos said having late-stage assets and a team fortified at MyoKardia really resonated with investors. SpaceX's huge public offering didn't hurt either.
Pharmaceutical Technology115d agoneutral
Kardigan targets IPO to support cardiology pipeline progressionKardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies further down the clinical pipeline.